ARTICLE | Management Tracks
Wigerinck to leave Galapagos; plus Kymera, Alladapt, Nurix, Alchemab, Novome and more
June 22, 2021 7:42 PM UTC
Piet Wigerinck will step down this year after serving as CSO for nine years at Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG), overseeing the Belgian biotech’s programs from the discovery of targets through clinical proof of concept. CMO Walid Abi-Saab, who joined the company in late 2017 to oversee late-stage development, will be responsible for early-stage activities as the company searches for a successor. The announcement follows a series of clinical setbacks for the Belgian biotech.
Kymera Therapeutics Inc. (NASDAQ:KYMR) hired Elaine Caughey as CBO. Caughey joins the protein degradation company from Cygnal Therapeutics Inc., where she was CBO. ...